AbbVie gave its payout a mighty boost just ahead of a major trial failure. Maybe now's a good time to look under the hood.
AbbVie Inc.'s (NYSE:ABBV) treated shareholders to some hefty
dividend bumps since its inception five years ago, but a 35% raise announced in
February was the biggest yet. Not long after announcing the payout boost and
another $10 billion stock repurchase program, a high-profile clinical trial
failure knocked AbbVie's stock down a few pegs.
At recent prices, AbbVie shares offer a nice 4% yield.
That's more than twice as much as you'll get from the average dividend-paying
stock in the benchmark S&P 500 index. If you're a cautious investor worried
about a dividend that looks too good to be true, here's what you need to know
about the pillars supporting AbbVie's rapidly rising payouts.
No comments:
Post a Comment